WO2003000182A2 - Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie - Google Patents

Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie Download PDF

Info

Publication number
WO2003000182A2
WO2003000182A2 PCT/US2002/019464 US0219464W WO03000182A2 WO 2003000182 A2 WO2003000182 A2 WO 2003000182A2 US 0219464 W US0219464 W US 0219464W WO 03000182 A2 WO03000182 A2 WO 03000182A2
Authority
WO
WIPO (PCT)
Prior art keywords
cachexia
patient
pparα
effective
compounds
Prior art date
Application number
PCT/US2002/019464
Other languages
English (en)
Other versions
WO2003000182A3 (fr
Inventor
Samuel D. Wright
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to US10/482,233 priority Critical patent/US20040167107A1/en
Priority to AU2002316299A priority patent/AU2002316299A1/en
Publication of WO2003000182A2 publication Critical patent/WO2003000182A2/fr
Publication of WO2003000182A3 publication Critical patent/WO2003000182A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • Peroxisome proliferator-activated receptors are transcription factors belonging to the nuclear receptor supergene family. Three distinct PPARs, termed ⁇ , ⁇ and ⁇ , have been described. Each one is encoded by a separate gene. PPARs are characterized by distinct tissue distribution patterns and metabolic functions. PPAR ⁇ is a homologous transcription factor with a distinct expression pattern being present in liver, monocytes, smooth muscle cells and other tissues.
  • Cachexia is a metabolic condition characterized by weight loss and muscle wasting. It is associated with a wide range of conditions including inflammation, heart failure and malignancies, and is well known and described in the clinical literature ⁇ J. Natl. Cancer h st. 89(23): 1763-1773 (1997) ⁇ .
  • the mechanistic derangements underlying cachexia are not known, but it is clear that a negative energy balance obtains in the face of severe weight loss.
  • Energy sparing mechanism normally operative in starvation are not brought into play with resultant energy loss. Starvation induces a wide variety of physiologic charges, and recent work has shown a key role for the nuclear hormone receptor, PPAR ⁇ .
  • PPAR ⁇ likely mediates starvation responses by regulating the expression of a wide variety of genes involved in metabolism. Starvation is known to induce PPAR ⁇ function, presumably because the fatty acids liberated from adipose tissue during starvation are ligands for PPAR ⁇ . It may thus be assumed that PPAR ⁇ agonists such as fibrates will entrain changes in gene expression that spare energy.
  • the object of the current invention is a method of treating cachexia comprised of administering a PPAR ⁇ agonist, such as a fibrate, to a cachetic individual.
  • the present invention relates to a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to treat or prevent cachexia.
  • Combination therapies and pharmaceutical compositions for treating or preventing cachexia are also encompassed.
  • the present invention relates to a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to treat or prevent cachexia.
  • An embodiment of the invention encompasses a method for treating cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to treat of cachexia.
  • Another embodiment of the invention encompasses a method for preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to prevent cachexia.
  • Another embodiment of the invention encompasses a method for treating or preventing cachexia in a patient in need thereof comprising concomitantly administering a glucocorticoid with a PPAR ⁇ agonist to said patient in amounts that are effective to treat cachexia.
  • Glucocorticoids are known in the art.
  • a preferred glucocorticoid is dexamethasone.
  • glucocorticoids include, for example, aldosterone, beclomethasone, betamethasone, budesonide, cloprednol, cortisone, cortivazol, eoxycortone, desonide, desoximetasone, difluorocortolone, luclorolone, flumethasone, flunisolide, fluocinolone, luocinonide, fluocortin butyl, fluorocortisone, fluorocortolone, fluorometholone, flurandrenolone, fluticasone, alcinonide, hydrocortisone, comethasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortol, triamcinolone, and others, and their respective pharmaceutically acceptable derivatives, such as beclomethasone diproprionate, dexa
  • concomitant means that the two drugs are administered either in combination or that one drug is administered separately while the first drug is present in a therapeutically effective amount.
  • Another embodiment of the invention encompasses a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to treat or prevent cachexia, wherein the patient is a cancer patient.
  • Another embodiment of the invention encompasses a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to treat or prevent cachexia, wherein the patient is an acquired immunodeficiency syndrome patient.
  • Another embodiment of the invention encompasses a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR ⁇ agonist in an amount that is effective to treat or prevent cachexia, wherein the patient is a cardiac patient.
  • the invention also encompasses a pharmaceutical composition comprising a PPAR ⁇ agonist and a glucocorticoid in combination with a pharmaceutically acceptable carrier.
  • PPAR ⁇ agonists Compounds that are PPAR ⁇ agonists are known in the art and include fenofibrate, clofibrate, gemfibrozil and benzafibrate. PPAR ⁇ agonists that also interact with PPAR ⁇ are also contemplated for purposes of this specification. Other examples of compounds which are PPAR ⁇ agonists are found in the following patents and published applications: WO 97/28115 published on August 7, 1997; WO 00/78312 published on December 28, 2000; WO 00/78313 published on December 28, 2000; U.S. No. 5,847,008 granted on December 8, 1998; U.S. No. 5,859,051 granted on January 12, 1999; U.S. No.
  • compositions of the present invention comprise a
  • PPAR ⁇ agonist as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.
  • composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • the present compounds can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • oral liquid preparations such as, for example, suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparation
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
  • the active compounds can also be administered intranasally as, for example, liquid drops or spray.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • a liquid carrier such as a fatty oil.
  • Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • sucrose as a sweetening agent
  • methyl and propylparabens as preservatives
  • a dye and a flavoring such as cherry or orange flavor.
  • the present compounds may also be administered parenterally.
  • Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates.
  • Salts derived from pharmaceutically acceptable organic non- toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as arg
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • references to PPAR ⁇ agonists or compounds which are PPAR ⁇ agonists include the pharmaceutically acceptable salts thereof.
  • the compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
  • the present invention is meant to comprehend all such isomeric forms.
  • the compounds encompassed by the present invention may contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
  • the compounds encompassed by the present invention may exist with different points of attachment of hydrogen, referred to as tautomers.
  • tautomers Such an example may be a ketone and its enol form, known as keto-enol tautomers.
  • keto-enol tautomers The individual tautomers as well as mixtures thereof are encompassed with compounds of Formula U and Ha.
  • the compounds encompassed by the present invention may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof.
  • a suitable solvent for example methanol or ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.
  • any enantiomer of the compounds of the present invention may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
  • Any suitable route of administration may be employed for providing a mammal, and especially a human, with an effective dosage of the present compounds for the treatment or prevention of cachexia.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • the compounds are administered orally.
  • the effective dosage of the active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • the compound When treating or preventing cachexia generally satisfactory results are obtained when the compound is administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dosage is from about 1.0 milligrams to about 1000 milligrams, preferably from about 1 milligrams to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the compounds of the present invention for use in treating or preventing cachexia may be used in combination with other drugs for the treatment or prevention of cachexia.
  • Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
  • a pharmaceutical composition in unit dosage form containing such other drugs and the PPAR ⁇ agonist is preferred. It is also contemplated that when used in combination with one or more other active ingredients, the compound of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the present invention.
  • a preferred combination therapy for the treatment or prevention of cachexia is a PPAR ⁇ agonist and a glucocorticoid.
  • the PPAR ⁇ agonist and glucocorticoid are presented in a ratio that is consistent with the manifestation of the desired effect.
  • the ratio by weight of the PPAR ⁇ agonist to the glucocorticoid will suitably be approximately between 0.001 to 1 and 1000 to 1, and especially between 0.01 to 1 and 100 to 1.
  • Expression constructs are prepared by inserting cDNA sequences encoding the ligand binding domains of human PPAR ⁇ or PPAR ⁇ adjacent to the yeast GAL4 transcription factor DNA binding domain in the mammalian expression vector pcDNA3 to create pcDNA3-hPPAR ⁇ /GAL4 and pcDNA3-hPPAR ⁇ /GAL4, respectively.
  • the GAL4-responsive reporter construct, pUAS(5X)-tk-luc contains 5 copies of the GAL4 response element placed adjacent to the thymidine kinase minimal promoter and the lucif erase reporter gene.
  • the transfection control vector, pCMV-lacZ contains the galactosidase Z gene under the regulation of the cytomegalovirus promoter.
  • COS-1 cells are seeded at 1.2 X 10 ⁇ cells/well in 96 well plates in Dulbecco's modified Eagle medium (high glucose) containing 10% charcoal stripped fetal calf serum, nonessential amino acids, 100 units/ml Penicillin G and 100 ⁇ g/ml Streptomycin sulfate at 37°C in a humidified atmosphere of 10% CO2- After 24 h, transfections are performed with Lipofectamine (Gibco-BRL,
  • Transfection mixes contain 0.00075 ⁇ g of PPAR ⁇ /GAL4 or PPAR ⁇ /GAL4 expression vector, 0.045 ⁇ g of reporter vector pUAS(5X)-tk-luc and 0.0002 ⁇ g of pCMV-lacZ vector as an internal control of transfection efficiency.
  • Compounds are characterized by incubation with transfected cells for 48h across a range of 8-12 concentrations from 0.1 nM to 50 uM.
  • Cell lysates are prepared from washed cells using Reporter Lysis Buffer (Promega) according to the manufacturer's directions.
  • Lucif erase activity in cell extracts is determined using Luciferase Assay Buffer (Promega) in a ML3000 luminometer (Dynatech Laboratories), ⁇ -galactosidase activity is determined using ⁇ - D-galactopyranoside (Calbiochem-Novabiochem, LaJolla, CA) as described by
  • Rosiglitazone can be used as a standard for human PPAR ⁇ activity.
  • EC50 values for Rosiglitazone in the hPPAR ⁇ /GAL4 assay usually range from 20-40 nM.
  • Fenofibrate can be used as a standard for hPPAR ⁇ activity.
  • EC50 values for Fenofibrate in the hPPAR ⁇ /GAL4 assay usually range from 5-20 uM.
  • This assay measures the ability of compounds to promote the association of PPAR ⁇ (or its isolated ligand binding domain) or PPAR ⁇ (or its isolated ligand binding domain) with a protein (or portion of a protein) that is (or is derived from) a co-activator molecule such as Creb Binding Protein (CBP) or Steroid Receptor Coactivator 1 (SRC-1) and can be used to identify compounds with both PPAR ⁇ and PPAR ⁇ agonist activity.
  • CBP Creb Binding Protein
  • SRC-1 Steroid Receptor Coactivator 1
  • An alternative to measuring agonist activity of compounds in cell- based transactivation assays or cell-free co-activator association assays is to determine that compounds can function as ligands by binding to both PPAR ⁇ and PPAR ⁇ .
  • Compounds with half -maximal concentration potencies (IC5 ⁇ 's or KI's) for displacement of radioligand binding to hPPAR ⁇ vs. hPPAR ⁇ that differ by less than 30-fold and preferably less than 10-fold can be considered as dual ligands.
  • Human PPAR ⁇ 2 and human PPAR ⁇ were expressed as a GST-fusion protein in E. coli.
  • the full length human cDNA for PPAR ⁇ 2 was subcloned into the pGEX-2T expression vector (Pharmacia).
  • the full length human cDNA for PPAR ⁇ was subcloned into the pGEX-KT expression vector (Pharmacia).
  • E. coli containing the respective plasmids were propagated, induced, and harvested by centrifugation. The resuspended pellet was broken in a French press and debris was removed by centrifugation at 12,000Xg.
  • Recombinant human PPAR receptors were purified by affinity chromatography on glutathione sepharose. After application to the column, and one wash, receptor was eluted with glutathione. Glycerol (10%) was added to stabilize the receptor and aliquots were stored at -80 °C.
  • TEGM 10 mM Tris, pH 7.2, 1 mMEDTA, 10% glycerol, 7 ⁇ L/100 ml ⁇ -mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 5 ⁇ g/mL aprotinin, 2 ⁇ g/mL leupeptin, 2 ⁇ g/mL benzamidine and 0.5 mM PMSF) containing 0.1% non-fat dry milk and 10 nM [-1H2] L-746,962, (21 Ci/mmole), ⁇ test compound.
  • TEGM 10 mM Tris, pH 7.2, 1 mMEDTA, 10% glycerol, 7 ⁇ L/100 ml ⁇ -mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 5 ⁇ g/mL aprotinin, 2 ⁇ g/mL leupeptin, 2 ⁇ g/mL
  • a human PPAR ⁇ binding assay an aliquot of receptor was incubated in TEGM (10 mM Tris, pH 7.2, 1 mM EDTA, 10% glycerol, 7 ⁇ L/100 ml ⁇ -mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 5 ⁇ g/mL aprotinin, 2 ⁇ g/mL leupeptin, 2 ⁇ g/mL benzamide and 0.5 mM PMSF) containing 0.1% non-fat dry milk and 5.0 nM [3H2]L-783483, ⁇ test compound. Assays were incubated for TEGM (10 mM Tris, pH 7.2, 1 mM EDTA, 10% glycerol, 7 ⁇ L/100 ml ⁇ -mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 5 ⁇ g/mL aprot
  • This assay measures the ability of cells to convert MTS tetrazolium into formazan, using the AQ ue0Us cell proliferation assay kit (Promega, Madison, WI). This conversion is presumably accomplished by NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells.
  • the assay is described in Shu, et al., Biochemical and Biophysical Research Communications, vol. 267, pp. 345-349 (2000).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode destinée au traitement ou à la prévention de la cachexie chez un patient, consistant à administrer une dose efficace d'un agoniste du récepteur PPARα au patient pour traiter ou prévenir la cachexie. L'invention concerne également des thérapies combinées et des compositions pharmaceutiques destinées au traitement ou à la prévention de la cachexie.
PCT/US2002/019464 2001-06-22 2002-06-19 Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie WO2003000182A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/482,233 US20040167107A1 (en) 2002-06-19 2002-06-19 Ppar-alpha ligands for the treatment or prevention of cachexia
AU2002316299A AU2002316299A1 (en) 2001-06-22 2002-06-19 Ppar-alpha ligands for the treatment or prevention of cachexia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30027401P 2001-06-22 2001-06-22
US60/300,274 2001-06-22

Publications (2)

Publication Number Publication Date
WO2003000182A2 true WO2003000182A2 (fr) 2003-01-03
WO2003000182A3 WO2003000182A3 (fr) 2003-05-08

Family

ID=23158415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019464 WO2003000182A2 (fr) 2001-06-22 2002-06-19 Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie

Country Status (2)

Country Link
AU (1) AU2002316299A1 (fr)
WO (1) WO2003000182A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883842B2 (en) 2004-08-13 2011-02-08 Invidumed GmbH Use of C3a and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036579A1 (fr) * 1996-03-30 1997-10-09 Glaxo Group Limited Utilisation d'agonistes du recepteur alpha active par un proliferateur de peroxysome pour traiter l'obesite
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036579A1 (fr) * 1996-03-30 1997-10-09 Glaxo Group Limited Utilisation d'agonistes du recepteur alpha active par un proliferateur de peroxysome pour traiter l'obesite
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883842B2 (en) 2004-08-13 2011-02-08 Invidumed GmbH Use of C3a and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system

Also Published As

Publication number Publication date
WO2003000182A3 (fr) 2003-05-08
AU2002316299A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
US20030055027A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
Ge et al. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development
US20050215537A1 (en) Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US20060058274A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
EP1868685A2 (fr) INHIBITEURS DE LA 11ßG(B)-HYDROXYSTEROIDE DESHYDROGENASES
CA2517588A1 (fr) Combinaison d'un antagoniste de recepteur d'aldosterone et d'un agent anti-diabetique
US20030220312A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001279050A1 (en) Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
Coghlan et al. The pursuit of differentiated ligands for the glucocorticoid receptor
US20040214804A1 (en) Combination of an aldosterone receptor antagonist and an anti-obesity agent
JP2005526843A (ja) 電気痙攣療法（「ｅｃｔ」）に対する治療応答を増大させるための方法
US20030220310A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20040115127A1 (en) Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
EP1389044A1 (fr) Agonistes ou ligands ppar-alpha-gamma destines au traitement d'inflammations
US20040248863A1 (en) Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflamation
WO2003000182A2 (fr) Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie
US20040167107A1 (en) Ppar-alpha ligands for the treatment or prevention of cachexia
US10039772B2 (en) Methods and compositions for treating alcohol use disorders
US20040116327A1 (en) Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
NO332723B1 (no) Anvendelse av glukokortikoidreseptorantagonist for fremstilling av medikamenter til inhibering av kognitiv svekkelse hos voksne med Downs syndrom
Schulz et al. Novel ligands: fine tuning the transcriptional activity of the glucocorticoid receptor
AU2002256250A1 (en) Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
Anderson et al. In vivo evaluation of 11β-hydroxysteroid dehydrogenase activity in the rabbit eye
AU2002303366A1 (en) Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
EP3599243A1 (fr) Composés de type 17bêta-hétérocyclyl-digitalis pour le traitement de l'insuffisance cardiaque

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10482233

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP